Sirtex Medical

The share price of liver cancer treatment provider Sirtex Medical is down 13% since our update of the company’s profit result on 29 Aug 11 (Speculative Buy – $4.95). There’s been no negative news of note; on the contrary, the company reported total dose sales rose 11% in the first quarter this financial year. Strong growth of 19% was reported for each of the US and Asia-Pacific regions, although dose sales fell 7% in Europe due to the summer holiday period. Dose sales won’t rise in a consistent fashion each quarter, but management expects a recovery in Europe in...

The share price of liver cancer treatment provider Sirtex Medical is down 13% since our update of the company’s profit result on 29 Aug 11 (Speculative Buy – $4.95). There’s been no negative news of note; on the contrary, the company reported total dose sales rose 11% in the first quarter this financial year.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles